Track topics on Twitter Track topics that are important to you
We list hundreds of Clinical Trials about "Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.
We have published hundreds of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) news stories on BioPortfolio along with dozens of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) Clinical Trials and PubMed Articles about Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) Companies in our database. You can also find out about relevant Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) Drugs and Medications on this site too.
The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM, and 3-4 years for AA. Initial therapy consists of either surgical resection, external beam radiation or both. All patients experience a recurrence after first-line therapy, so im...
A recent study by Plotkin et al. showed that bevacizumab (Avastin) treatment was followed by clinically meaningful hearing improvement, tumor-volume reduction, or both in some, but not all, patients with Vestibular Schwannoma (VS) who were at risk for complete hearing loss or brain-stem compression from growing VS. Because of the promising results in preliminary studies of Bevacizumab and because of significant experience with the safety of the dosages proposed in this study, t...
The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM, and 3-4 years for AA. Initial therapy consists of either surgical resection, external beam radiation or both. All patients experience a recurrence after first-line therapy, so ...
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).
Our hypothesis is that this study design, in which bevacizumab is added to one of six single agent chemotherapies with proven activity in metastatic breast cancer, will result in regression or stabilization of this disease in a safe and tolerable manner.
This is a phase 1b interventional trial of bevacizumab (Avastin®) to evaluate the tolerability/safety and preliminary efficacy of bevacizumab (Avastin®) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). A single infusion of Avastin® is added to standard-of-care high dose steroids and an additional dose of Avastin® is added to plasma exchange (if necessary). The...
This open-label single arm study will evaluate the efficacy and safety of Avastin added to XELOX in patients with metastatic colorectal cancer and disease progression on 1st line therapy with FOLFIRI plus Avastin. Patients will receive Avastin (7.5mg/kg iv infusion every 3 weeks) and standard XELOX (Xeloda plus oxaliplatin) chemotherapy. The anticipated time on study treatment is until disease progression and the target sample size is 100 individuals.
Chemotherapy and bevacizumab is given for 4 months. Patients who have not progressed will continue with maintenance treatment with either bevacizumab (Avastin) alone, or bevacizumab and erlotinib (Tarceva).
The multi-center, open-label study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with modified FOLFOX6 in patients with colorectal cancer and metastases confined to the liver. Patients will receive Avastin 5mg/kg and mFOLFOX6 (oxaliplatin, folinic acid, 5-fluorouracil) every 2 weeks for 12 cycles. In between these cycles, patients will undergo liver surgery if operable. After the 12 treatment cycles, patients will receive Avastin alone for 52 wee...
This open-label, multicenter study will evaluate the safety and efficacy of RO53 23441 in combination with Avastin (bevacizumab) in patients with recurrent gliob lastoma. In the dose-finding part, patients will receive intravenous escalating doses of RO5323441 in combination with 10 mg/kg Avastin once every two weeks. In the efficacy-finding part, patients will be randomized to receive the establish ed dose (from the dose-finding part) of RO5323441 plus Avastin or Avastin alone...
This randomized, non-comparative study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with recurrent glioblastoma. Patients will be randomized to receive Avastin 10 mg/kg intravenously every 2 weeks or fotemustin e 75 mg/m2 on days 1, 8 and 15, followed by, after a 5 weeks interval, 100 mg/m2 intravenously every 3 weeks. Treatment with fotemustine serves as a calibration arm and no formal efficacy comparison will be made between the two treatment ar ...
The purpose of this to assess pharmacokinetic bioequivalence between two bevacizumab products, RPH-001 (TRPHARM) and EU sourced Avastin® (Roche), after single IV administration at 5 mg/kg fixed dose.
This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine)versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line therapy with docetaxel + Avastin.Eligible patients will receive up to 6 x 3week cycles of treatment with Avastin (15mg/mg iv on day 1 of each cycle) + docetaxel (75-100mg/m2 iv on day 1 of each cycle).Those patients who do not progress will be randomized to...
Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.
This observational study will assess the treatment duration, progression-free survival, reason for stopping treatment and patient and tumor characteristics of bevacizumab [Avastin] treatment in patients with metastatic colorectal cancer. Data will be collected for approximately 34 months. The target sample size is >300 patients.
To assess the use of Avastin for the management of serosanguinous maculopathy
Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.
This open-label, randomized, multicenter study will evaluate the efficacy and sa fety of Avastin (bevacizumab) in combination with standard of care treatment in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Patients will be enrolled at documentation of progression of disease (PD) after 4-6 cycl es of first-line treatment with Avastin plus a platinum doublet-containing thera py and a minimum of two cycles of Avastin maintenance treatment prior to PD. Pa...
Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a first or second recurrence of glioblastoma multiforme (GBM), in an attempt to manage life threatening recurrence of Grade IV malignant glioma.
This study will assess the efficacy and safety of two different neoadjuvant treatment approaches including Avastin in newly diagnosed patients with high risk locally advanced rectal cancer. Patients will be randomized into one of two treatment arms. Arm A will undergo an induction phase, consisting of 6 cycles of Avastin (5mg/kg iv) plus FOLFOX 4, followed by a 7 week chemoradiation phase, consisting of Avastin (5mg/kg iv) plus 5-FU plus radiotherapy, followed by surgery. Arm B...
This multicenter, double-blind, placebo-controlled, randomized study will evalua te the efficacy and safety of the addition of Avastin (bevacizumab) or placebo t reatment to lomustine in second-line treatment and standard of care (SOC) in thi rd-line treatment following disease progression after first-line treatment in pa tients with newly diagnosed glioblastoma. All enrolled patients will receive fir st-line treatment with radiotherapy, temozolomide and Avastin (10 mg/kg/week ...
This randomized, open-label study will evaluate the safety and efficacy of Avastin (Bevacizumab) added to standard mFOLFOX6 chemotherapy in treatment-naïve patients with Stage IV metastatic colorectal cancer. According to K-RAS gene mutation status, patients will be assigned or randomized to receive either Avastin 5 mg/kg intravenously (iv) on Day 1 of each 2-week cycle or cetuximab 400 mg/m2 iv on Day 1 followed by 250 mg/m2 iv every week, in addition to mFOLFOX6 every 2 week...
This 3 arm study will evaluate the efficacy and safety of adding Avastin versus placebo to a standard chemotherapeutic regimen in patients with advanced or recu rrent non-squamous non-small cell lung cancer (NSCLC) who have not received prio r chemotherapy. The anticipated time of study treatment is until disease progres sion, and the target sample size is 500+ individuals.
The primary purpose of the study is to investigate whether patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration, receiving triple or double therapy compared to monotherapy with Avastin will reduce the intervention rate with equivalent safety and efficacy.
This study will provide preliminary data on the dose and dose interval related effects of intravitreally administered Avastin on retinal thickness and visual acuity in subjects with Diabetic Macular Edema (DME) to aid in planning a phase 3 trial. In addition, this study will provide preliminary data on the safety of intravitreally administered Avastin in subjects with DME.